Overexpression of the α-synuclein (α-Syn) gene is the hallmark in Parkinson’s disease (PD) and the therapeutics pertain to the delivery of a shorter RVG linked to the negatively charged siRNA to suppress α-Syn. This evidence concerns the gene SNCA and Parkinson disease.